WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke CYTOMX wurde als Wortmarke am 19.10.2017 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1406697 |
| Länder | 
|
| Basismarke |
Nr. ,
30. September 2024
|
| Anmeldedatum | 19. Oktober 2017 |
| Ablaufdatum | 19. Oktober 2027 |
Markeninhaber
151 Oyster Point Blvd,
Suite 400
US
Suite 400
US
Markenvertreter
Sughrue Mion, PLLC,
2000 Pennsylvania Ave. NW.
US
Waren und Dienstleistungen
01
Biochemicals for scientific, laboratory, and research use,
namely, proteolytically- activatable, protease-activatable,
or proteolytically activated or protease-activated
immunoglobulin and antigen-binding fragments for binding to
tissue, cells and antigens; diagnostic kits for scientific,
laboratory, and research use comprising
proteolytically-activatable or protease-activatable,
proteolytically-activated or protease-activated
immunoglobulin and antigen-binding fragments for binding to
tissue, cells, and antigens; immunoglobulin and
antigen-binding fragments for drug conjugation and targeted
cell binding for laboratory and research use; assays and
reagents for use in scientific, laboratory and research
purposes; biochemical test kits comprising assays and
reagents for scientific, laboratory and research purposes;
assay kits comprising assays and reagents for measuring,
monitoring, testing and analyzing proteolytic activation and
antibody binding for scientific, laboratory and research
use
05
Biological drugs for use in treating cancer, infections,
autoimmunity, and inflammation; therapeutic and diagnostic
agents and preparations for use in therapies and diagnosis
for cancer, infections, autoimmunity, and inflammation;
biochemicals, immunoglobulins and antigen-binding fragments
for use in therapies and diagnosis for cancer, infections,
autoimmunity, and inflammation; engineered cell therapies
for medical purposes, namely, for use in treating cancer,
infections, autoimmunity, and inflammation; therapeutic and
diagnostic agents, preparations and substances for medical
purposes; immune modulators, immunoglobulin drug conjugates,
immunotherapies and therapeutic and diagnostic agents,
preparations and substances in the field of dysregulated
proteolytic activity for medical purposes; immunotherapies
and therapeutic and diagnostic agents, preparations and
substances in the field of cancer, infections, autoimmunity,
and inflammation for medical purposes; assays and reagents
for use in medical, diagnostic and therapeutic purposes;
biochemical test kits comprised of assays and reagents for
medical, diagnostic and therapeutic purposes; assay kits
comprised of assays and reagents for measuring, monitoring,
testing and analyzing proteolytic activation, antibody
binding, therapeutic treatments and patient recovery for
medical, diagnostic and therapeutic purposes; assay kits
comprised of assays and reagents for use in identifying
candidate patient populations for specific therapeutic
treatments
42
Scientific research and development in the field of
therapeutic biochemicals, engineered cell therapies and
immunotherapy, oncology and dysregulated proteolytic
activity; medical and scientific research and development
for agents, preparations, products and technology in the
field of dysregulated proteolytic activities; providing
medical and scientific research information in the fields of
biochemicals, engineered cell therapies, immunotherapy,
oncology and dysregulated proteolytic activity; scientific
investigations for medical purposes; medical research;
providing scientific and medical research information and
analysis relating to biochemicals, engineered cell therapies
and immunotherapy, proteolytic activation, antibody binding,
therapeutic treatments, patient recovery, and the
identification of candidate patients for specific
therapeutic treatments; testing, research, design and
development services in the field of biochemicals for
scientific and medical research purposes; research, design
and development of assays for measuring, monitoring, testing
and analyzing proteolytic activation, antibody binding,
therapeutic treatments and patient recovery, and for
identifying candidate patient populations for specific
therapeutic treatments; providing technical support and
consultation services relating to antibody selection and
use, namely, providing technical scientific research
consultation services; providing search engines for online
databases for obtaining data, namely, for searching,
retrieving, and providing information on antibodies and
research topics pertaining to antibodies on a global
computer network
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 18. November 2021 | 2021/49 Gaz | US | RAW: Partial Ceasing Effect |
| 16. November 2021 | 2021/49 Gaz | KR | RAW: Rule 18ter(4) protected goods and services |
| 02. Januar 2020 | 2020/1 Gaz | KR | Ablehnung |
| 01. Oktober 2019 | 2019/42 Gaz | IN | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 03. September 2019 | 2019/41 Gaz | IL | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 08. August 2019 | 2019/33 Gaz | JP | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 26. Juli 2019 | 2019/31 Gaz | RU | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 29. März 2019 | 2019/14 Gaz | MX | Ablehnung |
| 14. März 2019 | 2019/11 Gaz | JP | Ablehnung |
| 07. März 2019 | 2019/10 Gaz | KR | Ablehnung |
| 06. Februar 2019 | 2019/15 Gaz | AU | Ablehnung |
| 03. Januar 2019 | 2019/1 Gaz | SG | Ablehnung |
| 27. Dezember 2018 | 2019/2 Gaz | IL | Ablehnung |
| 25. Dezember 2018 | 2019/1 Gaz | RU | Ablehnung |
| 23. November 2018 | 2018/51 Gaz | CN | Ablehnung |
| 30. Oktober 2018 | 2018/44 Gaz | NZ | Ablehnung |
| 21. September 2018 | 2018/44 Gaz | US | RAW: Division or Merger of Basic Registration |
| 04. August 2018 | 2018/36 Gaz | RAW: Limitation | |
| 25. Juni 2018 | 2018/27 Gaz | IN | Ablehnung |
| 19. Oktober 2017 | 2018/22 Gaz | US | Eintragung |
ID: 141406697